Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein.

Protein-protein interacting surfaces are usually large and intricate, making the rational design of small mimetics of these interfaces a daunting problem. On the basis of a structural similarity between the CDR2-like loop of CD4 and the beta-hairpin region of a short scorpion toxin, scyllatoxin, we transferred the side chains of nine residues of CD4, central in the binding to HIV-1 envelope glycoprotein (gp120), to a structurally homologous region of the scorpion toxin scaffold. In competition experiments, the resulting 27-amino acid miniprotein inhibited binding of CD4 to gp120 with a 40 microM IC(50). Structural analysis by NMR showed that both the backbone of the chimeric beta-hairpin and the introduced side chains adopted conformations similar to those of the parent CD4. Systematic single mutations suggested that most CD4 residues from the CDR2-like loop were reproduced in the miniprotein, including the critical Phe-43. The structural and functional analysis performed suggested five additional mutations that, once incorporated in the miniprotein, increased its affinity for gp120 by 100-fold to an IC(50) of 0.1-1.0 microM, depending on viral strains. The resulting mini-CD4 inhibited infection of CD4(+) cells by different virus isolates. Thus, core regions of large protein-protein interfaces can be reproduced in miniprotein scaffolds, offering possibilities for the development of inhibitors of protein-protein interactions that may represent useful tools in biology and in drug discovery.

[1]  W. Hendrickson,et al.  CD4: its structure, role in immune function and AIDS pathogenesis, and potential as a pharmacological target. , 1991, Current opinion in biotechnology.

[2]  A. Braisted,et al.  Minimizing a binding domain from protein A. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Harrison,et al.  The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure , 1992, The Journal of experimental medicine.

[4]  C. Vita,et al.  Novel miniproteins engineered by the transfer of active sites to small natural scaffolds. , 1998, Biopolymers.

[5]  H. Buc,et al.  HIV-1 reverse transcription. A termination step at the center of the genome. , 1994, Journal of molecular biology.

[6]  M. Uhlén,et al.  Scaffolds for engineering novel binding sites in proteins. , 1997, Current opinion in structural biology.

[7]  Joseph Sodroski,et al.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.

[8]  T. Malliavin,et al.  Gifa V. 4: A complete package for NMR data set processing , 1996, Journal of biomolecular NMR.

[9]  D. Littman,et al.  Fusion-competent vaccines: broad neutralization of primary isolates of HIV. , 1999, Science.

[10]  Q. Sattentau,et al.  Identification of the residues in human CD4 critical for the binding of HIV , 1989, Cell.

[11]  D. Brainard,et al.  Color, contrast sensitivity, and the cone mosaic. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Peter D. Kwong,et al.  Crystal structure of an HIV-binding recombinant fragment of human CD4 , 1990, Nature.

[14]  L. Ylisastigui,et al.  HIV type 1 V3 peptide constructs act differently on HIV type 1 infection of peripheral blood lymphocytes and macrophages. , 1997, AIDS research and human retroviruses.

[15]  W. Hendrickson,et al.  Structures of an HIV and MHC binding fragment from human CD4 as refined in two crystal lattices. , 1994, Structure.

[16]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[17]  Flavio Toma,et al.  Structural basis for functional diversity of animal toxins , 1992 .

[18]  D. Littman Chemokine Receptors: Keys to AIDS Pathogenesis? , 1998, Cell.

[19]  S. Harrison,et al.  Peptide Ligands to Human Immunodeficiency Virus Type 1 gp120 Identified from Phage Display Libraries , 1999, Journal of Virology.

[20]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[21]  C. Roumestand,et al.  Refined structure of charybdotoxin: common motifs in scorpion toxins and insect defensins. , 1991, Science.

[22]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[23]  Luc Montagnier,et al.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus  LAV , 1984, Nature.

[24]  F M Poulsen,et al.  Accurate measurements of coupling constants from two-dimensional nuclear magnetic resonance spectra of proteins and determination of phi-angles. , 1991, Journal of molecular biology.

[25]  K. M. Hwang,et al.  Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. , 1988, Science.

[26]  D. Weiner,et al.  Design and synthesis of a CD4 beta-turn mimetic that inhibits human immunodeficiency virus envelope glycoprotein gp120 binding and infection of human lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[28]  D. Weiner,et al.  Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes , 1997, Nature Biotechnology.

[29]  C. Mullineaux,et al.  A proportion of photosystem II core complexes are decoupled from the phycobilisome in light‐state 2 in the cyanobacterium Synechococcus 6301 , 1990 .

[30]  M. Lazdunski,et al.  Solution conformation of leiurotoxin I (scyllatoxin) by 1H nuclear magnetic resonance , 1990, FEBS letters.

[31]  L. Presta,et al.  Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Roumestand,et al.  Scorpion toxins as natural scaffolds for protein engineering. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Q. Sattentau HIV gp120: double lock strategy foils host defences. , 1998, Structure.

[34]  M. Billeter,et al.  MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.

[35]  C. Vita,et al.  Changing the Structural Context of a Functional -Hairpin , 1996, The Journal of Biological Chemistry.

[36]  B. Cunningham,et al.  Minimization of a Polypeptide Hormone , 1995, Science.

[37]  M. Lazdunski,et al.  Scyllatoxin, a blocker of Ca(2+)-activated K+ channels: structure-function relationships and brain localization of the binding sites. , 1992, Biochemistry.

[38]  K. Wüthrich NMR of proteins and nucleic acids , 1988 .

[39]  J. Moore Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4. , 1990, AIDS.

[40]  M. Greaves,et al.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.